Drug Profile
Indometacin transdermal - NAL Pharma
Alternative Names: Indomethacin transdermal - NAL Pharma; NAL 1207Latest Information Update: 26 May 2022
Price :
$50
*
At a glance
- Originator NAL Pharma
- Class Analgesics; Antirheumatics; Chlorobenzenes; Indoles; Nonsteroidal anti-inflammatories; Small molecules
- Mechanism of Action Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Clinical Phase Unknown Pain
Most Recent Events
- 26 May 2022 Indometacin transdermal is still in clinical trials for Pain (NAL Pharma pipeline, May 2022)
- 28 Oct 2019 No recent reports of development identified for clinical-Phase-Unknown development in Pain in Unknown (Transdermal, Patch)
- 26 Aug 2016 Chemical structure information added